Table 6.
The relationship between the CCL2 and CCR2 genotypes and plasma MCP-1 levels in AD patients, MCI patients, and control subjects.
| CCL2 rs1024611 | Control (n = 120) | MCI (n = 66) | AD (n = 310) | AD and MCI (n = 376) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GG | AG | AA | GG | AG | AA | GG | AG | AA | GG | AG | AA | |
| MCP-1 levels | 220.8 ± 118.7 | 173.5 ± 67.5 | 183.8 ± 57.3 | 207.5 ± 76.7 | 211.9 ± 66.2 | 158.8 ± 20.5 | 244.3 ± 111.1 | 248.2 ± 97.4 | 240.3 ± 106.4 | 236.7 ± 105.7 | 241.7 ± 93.5 | 231.1 ± 103.7 |
| Additive model | p = 0.19, adjusted p = 0.30* | p = 0.32, adjusted p = 0.41* | p = 0.99, adjusted p = 0.81* | p = 0.94, adjusted p = 0.80* | ||||||||
| CCR2 rs1799864 | GG | AG | AA | GG | AG | AA | GG | AG | AA | GG | AG | AA |
| MCP-1 levels | 182.6 ± 83.7 | 209.6 ± 96.5 | 174.3 ± 51.4 | 189.3 ± 71.2 | 222.5 ± 46.2 | 310.5 ± 82.7 | 237.0 ± 98.6 | 249.1 ± 108.4 | 316.0 ± 87.3 | 228.2 ± 95.8 | 244.6 ± 100.9 | 315.4 ± 84.6 |
| Additive model | p = 0.23, adjusted p = 0.30* | p = 0.001, adjusted p = 0.003* | p = 0.01, adjusted p = 0.01* | p < 0.001, adjusted p = 0.001* | ||||||||
The values indicate means with standard deviations.
MCI, mild cognitive impairment; AD, Alzheimer’s disease; CCL2, Chemokine ligand 2; CCR2, CC-chemokine receptor 2; MCP-1, Monocyte chemoattractant protein-1.
*Multivariate linear regression model adjusting age, gender, APOE ε4 carrier status, and Charlson comorbidity index.